S&P 500   3,607.16 (-0.86%)
DOW   29,537.24 (-1.25%)
QQQ   296.24 (-0.93%)
AAPL   117.62 (+0.88%)
MSFT   211.18 (-1.88%)
FB   271.92 (-2.12%)
GOOGL   1,753.78 (-1.86%)
AMZN   3,142.12 (-1.67%)
TSLA   577.34 (-1.44%)
NVDA   523.45 (-1.32%)
BABA   264.96 (-4.17%)
CGC   28.40 (-2.07%)
GE   10.26 (-1.35%)
MU   64.11 (-0.19%)
AMD   89.44 (+2.58%)
T   28.87 (-0.55%)
NIO   51.28 (-5.04%)
F   9.11 (+0.22%)
ACB   10.72 (+2.39%)
NFLX   483.53 (-1.59%)
BA   210.82 (-2.62%)
GILD   59.73 (-0.50%)
DIS   146.92 (-0.14%)
S&P 500   3,607.16 (-0.86%)
DOW   29,537.24 (-1.25%)
QQQ   296.24 (-0.93%)
AAPL   117.62 (+0.88%)
MSFT   211.18 (-1.88%)
FB   271.92 (-2.12%)
GOOGL   1,753.78 (-1.86%)
AMZN   3,142.12 (-1.67%)
TSLA   577.34 (-1.44%)
NVDA   523.45 (-1.32%)
BABA   264.96 (-4.17%)
CGC   28.40 (-2.07%)
GE   10.26 (-1.35%)
MU   64.11 (-0.19%)
AMD   89.44 (+2.58%)
T   28.87 (-0.55%)
NIO   51.28 (-5.04%)
F   9.11 (+0.22%)
ACB   10.72 (+2.39%)
NFLX   483.53 (-1.59%)
BA   210.82 (-2.62%)
GILD   59.73 (-0.50%)
DIS   146.92 (-0.14%)
S&P 500   3,607.16 (-0.86%)
DOW   29,537.24 (-1.25%)
QQQ   296.24 (-0.93%)
AAPL   117.62 (+0.88%)
MSFT   211.18 (-1.88%)
FB   271.92 (-2.12%)
GOOGL   1,753.78 (-1.86%)
AMZN   3,142.12 (-1.67%)
TSLA   577.34 (-1.44%)
NVDA   523.45 (-1.32%)
BABA   264.96 (-4.17%)
CGC   28.40 (-2.07%)
GE   10.26 (-1.35%)
MU   64.11 (-0.19%)
AMD   89.44 (+2.58%)
T   28.87 (-0.55%)
NIO   51.28 (-5.04%)
F   9.11 (+0.22%)
ACB   10.72 (+2.39%)
NFLX   483.53 (-1.59%)
BA   210.82 (-2.62%)
GILD   59.73 (-0.50%)
DIS   146.92 (-0.14%)
S&P 500   3,607.16 (-0.86%)
DOW   29,537.24 (-1.25%)
QQQ   296.24 (-0.93%)
AAPL   117.62 (+0.88%)
MSFT   211.18 (-1.88%)
FB   271.92 (-2.12%)
GOOGL   1,753.78 (-1.86%)
AMZN   3,142.12 (-1.67%)
TSLA   577.34 (-1.44%)
NVDA   523.45 (-1.32%)
BABA   264.96 (-4.17%)
CGC   28.40 (-2.07%)
GE   10.26 (-1.35%)
MU   64.11 (-0.19%)
AMD   89.44 (+2.58%)
T   28.87 (-0.55%)
NIO   51.28 (-5.04%)
F   9.11 (+0.22%)
ACB   10.72 (+2.39%)
NFLX   483.53 (-1.59%)
BA   210.82 (-2.62%)
GILD   59.73 (-0.50%)
DIS   146.92 (-0.14%)
Log in
NYSE:NVTA

Invitae Stock Forecast, Price & News

$49.60
-0.46 (-0.92 %)
(As of 11/30/2020 11:39 AM ET)
Add
Compare
Today's Range
$48.30
Now: $49.60
$51.56
50-Day Range
$39.09
MA: $46.43
$53.31
52-Week Range
$7.41
Now: $49.60
$55.38
Volume48,037 shs
Average Volume3.02 million shs
Market Capitalization$8.76 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; and a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Read More
Invitae logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone415-374-7782
Employees1,300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$216.82 million
Book Value$3.93 per share

Profitability

Net Income$-241,960,000.00
Net Margins-182.73%

Miscellaneous

Market Cap$8.76 billion
Next Earnings Date2/17/2021 (Estimated)
OptionableOptionable
$49.60
-0.46 (-0.92 %)
(As of 11/30/2020 11:39 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Invitae (NYSE:NVTA) Frequently Asked Questions

How has Invitae's stock price been impacted by Coronavirus?

Invitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVTA stock has increased by 208.9% and is now trading at $48.96.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Invitae?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Invitae
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Invitae?

Wall Street analysts have given Invitae a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Invitae wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Invitae's next earnings date?

Invitae is scheduled to release its next quarterly earnings announcement on Wednesday, February 17th 2021.
View our earnings forecast for Invitae
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) issued its earnings results on Thursday, November, 5th. The medical research company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.18. The medical research company had revenue of $68.73 million for the quarter, compared to analysts' expectations of $59.36 million. Invitae had a negative net margin of 182.73% and a negative return on equity of 77.82%. Invitae's revenue for the quarter was up 21.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.82) earnings per share.
View Invitae's earnings history
.

What price target have analysts set for NVTA?

7 brokers have issued 12 month target prices for Invitae's stock. Their forecasts range from $20.00 to $48.00. On average, they expect Invitae's share price to reach $38.61 in the next twelve months. This suggests that the stock has a possible downside of 21.1%.
View analysts' price targets for Invitae
.

Who are some of Invitae's key competitors?

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), The Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

Who are Invitae's key executives?

Invitae's management team includes the following people:
  • Dr. Sean Emerson George, Co-Founder, Pres, CEO & Chairman (Age 46, Pay $666.79k)
  • Ms. Shelly D. Guyer, Chief Financial Officer (Age 60, Pay $566.77k)
  • Dr. Robert L. Nussbaum, Chief Medical Officer (Age 70, Pay $500.09k)
  • Mr. Lee Bendekgey, Chief Policy Officer (Age 62, Pay $566.77k)
  • Ms. Katherine A. Stueland, Chief Commercial Officer (Age 44, Pay $545.13k)
  • Mr. Alex Furman, Co-Founder, Culture Tsar & Head of People Analytics
  • Ms. Michele Cargill Ph.D., Co-Founder, Key Projects & Advisor to the CEO
  • Mr. Kenneth D. Knight, Chief Operating Officer (Age 60)
  • Mr. Robert F. Werner, Chief Accounting Officer (Age 47)
  • Mr. Layton Wedgeworth, Chief Technology Officer

When did Invitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (21.06%), Nikko Asset Management Americas Inc. (8.55%), Victory Capital Management Inc. (1.30%), Wells Fargo & Company MN (0.83%), Charles Schwab Investment Management Inc. (0.63%) and Lord Abbett & CO. LLC (0.45%). Company insiders that own Invitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Randal W Scott, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae
.

Which major investors are selling Invitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Cubist Systematic Strategies LLC, Squarepoint Ops LLC, State of New Jersey Common Pension Fund D, Teton Advisors Inc., CAPROCK Group Inc., Shelton Capital Management, and Commonwealth Equity Services LLC. Company insiders that have sold Invitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae
.

Which major investors are buying Invitae stock?

NVTA stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Victory Capital Management Inc., Lord Abbett & CO. LLC, Wells Fargo & Company MN, Allianz Asset Management GmbH, New York State Common Retirement Fund, State of Michigan Retirement System, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Invitae
.

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $48.96.

How big of a company is Invitae?

Invitae has a market capitalization of $8.65 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Invitae employs 1,300 workers across the globe.

What is Invitae's official website?

The official website for Invitae is www.invitae.com.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.